Visit COVID-19 resources

[Skip to Content]

TA294

Choice of anti VEGF agents for wet AMD treatments

Dec 22
2014

College statement on choice of two antiVEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). March2014

  • 22 December 2014